Last reviewed · How we verify
DA-3002
DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer.
DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.
At a glance
| Generic name | DA-3002 |
|---|---|
| Also known as | Recombinant Human Growth Hormone |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor Alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DA-3002 works by binding to estrogen receptors and promoting their proteasomal degradation, effectively removing the receptor protein from cells rather than simply blocking its activity. This mechanism eliminates both classical estrogen-dependent signaling and constitutive receptor activity, potentially overcoming resistance mechanisms that develop with standard endocrine therapies. The drug is designed to treat hormone receptor-positive breast cancer in postmenopausal women.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Vaginal dryness
Key clinical trials
- Efficacy and Safety of DA-3002 in Short Children Borns SGA. (PHASE3)
- A Clinical Study to Assess the Efficacy and Safety of DA-3002 (PHASE3)
- Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-3002 CI brief — competitive landscape report
- DA-3002 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI